← 프로그램 목록
ADCPhase 2Recruiting

Up-Titration (Patritumab Deruxtecan)

Daiichi Sankyo

비교

Patritumab Deruxtecan (Up-Titration)(Daiichi Sankyo)은 Non-Small Cell Lung Cancer Metastatic 표적 ADC로, Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 영역에서 개발·상용화 중입니다. 작용기전: antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 64% (ClinicalTrials.gov NCT04619004). 차별점: Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Nep.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 8일 (6일 전)PK/독성 2026년 7월 8일 (6일 전)

Non-Small Cell Lung Cancer Metastatic

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Recruiting

Technology

구조모아 · Exatecan/DXd (TOP1)구조모아 · MMAE (auristatin)

ADCINV) in patients with cancer

deruxtecan, sacituzumab govitecan, brentuximabvedo

linker technologies, and targets to expand the applicability of ADCs across broader NS

Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Nep

Mechanism of Action

antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer

Immune-Mediated Diseases: Beyond Multiple Sclerosis

DNA damage

biomarkers will give new insights on individual MTX metabolism and drug adherence

downregulation of DDR and cell cycle regulatory proteins, and tumour growth inhibition

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 88건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 2 · N/A · Phase 4
  • Status: No longer available · Completed · Recruiting
  • 주요 endpoint: Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan · Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan · Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan · Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinide · Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide
  • 등록된 결과: ORR 64%
  • PFS: 5.5
  • 핵심: This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or lo…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Patritumab Deruxtecan (Up-Titration)은 어떤 치료제인가요?
Patritumab Deruxtecan (Up-Titration)(Daiichi Sankyo)은 Non-Small Cell Lung Cancer Metastatic 표적 ADC로, Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Patritumab Deruxtecan (Up-Titration)의 임상 단계는?
Patritumab Deruxtecan (Up-Titration)의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.